Eficiencia de los agentes biológicos en el tratamiento de la psoriasis moderada-grave = EFFICIENCY OF BIOLOGIC AGENTS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASISBLASCO, A. J; LAZARO, P; FERRANDIZ, C et al.Actas dermo-sifiliográficas (Ed. impresa). 2009, Vol 100, Num 9, pp 792-803, issn 0001-7310, 12 p.Article

Intraocular inflammation in autoimmune diseasesPRAS, Eran; NEUMANN, Ron; ZANDMAN-GODDARD, Gisele et al.Seminars in arthritis and rheumatism. 2004, Vol 34, Num 3, pp 602-609, issn 0049-0172, 8 p.Article

Le traitement du psoriasis : sa stratégie et les nouvelles options = The treatment of psoriasis : basic principles and new optionsVEREECKEN, P; PROVOST, P; WILLAERT, F et al.Revue médicale de Bruxelles. 2007, Vol 28, Num 4, pp 336-344, issn 0035-3639, 9 p.Conference Paper

Efectos adversos observados durante la terapia biológica en la psoriasis. Resultados de una encuesta al Grupo Español de Psoriasis = Adverse reactions during biological therapy for psoriasis: Results of a survey of the Spanish Psoriasis GroupSANCHEZ-REGAN, M; DILME, E; RODRIGUEZ, M. A et al.Actas dermo-sifiliográficas (Ed. impresa). 2010, Vol 101, Num 2, pp 156-163, issn 0001-7310, 8 p.Article

Current challenges and future perspectives in the medical treatment of solid tumoursSOBRERO, A; DI BENEDETTO, M.European journal of cancer. Supplement (1990). 2008, Vol 6, Num 14, pp 91-93, issn 1359-6349, 3 p.Conference Paper

Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agentsPIPITONE, N; OLIVIERI, I; SALVARANI, C et al.Clinical and experimental rheumatology (Testo stampato). 2012, Vol 30, Num 1, issn 0392-856X, S139-S161, SUP70Article

Adverse reactions to biologic agents : Focus on autoimmune disease therapiesLEE, Susan J; KAVANAUGH, Arthur.Journal of allergy and clinical immunology. 2005, Vol 116, Num 4, pp 900-905, issn 0091-6749, 6 p.Article

Overview and recent developments in the medical management of paediatric uveitisPILLY, Bertrand; HEATH, Greg; TSCHUOR, Patrizia et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 13, pp 1787-1795, issn 1465-6566, 9 p.Article

Developing an effective treatment algorithm for rheumatoid arthritisKEYSTONE, Edward C; SMOLEN, Josef; RIEL, Piet Van et al.Rheumatology (Oxford. Print). 2012, Vol 51, issn 1462-0324, v48-v54, SUP5Article

Antirheumatic drugs in pregnancy and lactationTEMPRANO, Katherine K; BANDLAMUDI, Rama; MOORE, Terry L et al.Seminars in arthritis and rheumatism. 2005, Vol 35, Num 2, pp 112-121, issn 0049-0172, 10 p.Article

An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapyGOFFE, Bernard; PAPP, Kim; GRATTON, David et al.Clinical therapeutics. 2005, Vol 27, Num 12, pp 1912-1921, issn 0149-2918, 10 p.Article

Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasisMARYLES, S; ROZENBLIT, M; LEBWOHL, M et al.Journal of dermatological treatment. 2003, Vol 14, pp 7-16, issn 0954-6634, 10 p., SUP2Article

Psoriatic arthritis: current therapy and future directionsHUYNH, Doquyen; KAVANAUGH, Arthur.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 13, pp 1755-1764, issn 1465-6566, 10 p.Article

First-year purchases of disease-modifying drugs of incident patients with chronic juvenile arthritis in FinlandPOHJANKOSKI, H; LATVA, K; KAUTIAINEN, H et al.Clinical and experimental rheumatology (Testo stampato). 2011, Vol 29, Num 5, pp 878-881, issn 0392-856X, 4 p.Article

Combination systemic therapies in psoriatic arthritisDALY, Meaghan; ALIKHAN, Ali; ARMSTRONG, April W et al.Journal of dermatological treatment. 2011, Vol 22, Num 5, pp 276-284, issn 0954-6634, 9 p.Article

Treatment of Early Rheumatoid Arthritis: Concepts in ManagementHARAOUI, Boulos; POPE, Janet.Seminars in arthritis and rheumatism. 2011, Vol 40, Num 5, pp 371-388, issn 0049-0172, 18 p.Article

Pathogenesis and management of adult-onset still's diseaseEFTHIMIOU, Petros; GEORGY, Sharon.Seminars in arthritis and rheumatism. 2006, Vol 36, Num 3, pp 144-152, issn 0049-0172, 9 p.Article

Penile cancer: current therapy and future directionsSONPAVDE, G; PAGLIARO, L. C; BUONERBA, C et al.Annals of oncology. 2013, Vol 24, Num 5, pp 1179-1189, issn 0923-7534, 11 p.Article

Safety Profile of Abatacept in Rheumatoid Arthritis: A ReviewKHRAISHI, Majed; RUSSELL, Anthony; OLSZYNSKI, Wojciech P et al.Clinical therapeutics. 2010, Vol 32, Num 11, pp 1855-1870, issn 0149-2918, 16 p.Article

The role of tumor necrosis factor-alpha and other cytokines in depression: what dermatologists should knowKANNAN, Swati; HELLER, Misha M; LEE, Eric S et al.Journal of dermatological treatment. 2013, Vol 24, Num 2, pp 148-152, issn 0954-6634, 5 p.Article

REVIEW The Asia-Pacific consensus on ulcerative colitisCHOON JIN OOI; KWONG MING FOCK; QIN OUYANG et al.Journal of gastroenterology and hepatology. 2010, Vol 25, Num 3, pp 453-468, issn 0815-9319, 16 p.Article

Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos = SPANISH EVIDENCE-BASED GUIDELINES ONTHETREATMENT OF MODERATE-TO-SEVERE PSORIASIS WITH BIOLOGIC AGENTSPUIG, L; CARRASCOSA, J. M; LAGUARDA, S et al.Actas dermo-sifiliográficas (Ed. impresa). 2009, Vol 100, Num 5, pp 386-413, issn 0001-7310, 28 p.Article

Pathophysiology of asthma: What has our current understanding taught us about new therapeutic approaches?HOLGATE, Stephen T.Journal of allergy and clinical immunology. 2011, Vol 128, Num 3, pp 495-505, issn 0091-6749, 11 p.Article

Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer—an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009ADAM, R; HALLER, D. G; POSTON, G et al.Annals of oncology. 2010, Vol 21, Num 8, pp 1579-1584, issn 0923-7534, 6 p.Article

Uso de fàrmacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab = OFF-LABEL USE OF BIOLOGIC AGENTS IN THE TREATMENT OF DERMATOSIS, PART 2: ETANERCEPT, EFALIZUMAB, ALEFACEPT, RITUXIMAB, DACLIZUMAB, BASILIXIMAB, OMALIZUMAB, AND CETUXIMABGUHL, G; DIAZ-LEY, B; FERNANDEZ-HERRERA, J et al.Actas dermo-sifiliográficas (Ed. impresa). 2008, Vol 99, Num 1, pp 5-33, issn 0001-7310, 29 p.Article